Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Inclusion Criteria:

• Subject who completed the 24-week double-mask period of VGN-TED-301 and areproptosis non-responders (< 2 mm reduction in proptosis in the study eye) at Week 24of VGN-TED-301 study or proptosis responders at Week 24 who relapse during theFollow-Up period of VGN-TED-301

• Subject has not received any treatment for TED since Week 24 of VGN-TED-301

• Subjects must be euthyroid with the participant's baseline disease under control orhave mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and freetriiodothyronine levels [FT3] <50% above or below the normal limits) at Baseline.Every effort should be made to correct mild hypo- or hyperthyroidism promptly andmaintain the euthyroid state for the duration of the clinical trial

• Does not require immediate ophthalmic surgery, radiotherapy to orbits or otherophthalmological intervention at the time of Baseline and is not planning for anysuch treatment during the course of the study

Exclusion Criteria:

• The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.